Want to see HK:2185 full AI Analyst Report?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (2185) AI Stock Analysis
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
(HKEX:2185)
The score is driven down primarily by weak financial performance (ongoing heavy losses and cash burn) and bearish technicals (price below all key moving averages with negative MACD and very weak momentum). Valuation provides limited support because losses make the negative P/E hard to use and there is no dividend yield.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (2185) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 219.20M
- Dividend Yield
- ―
- Average Volume (3M)
- 120.90K
- Price to Earnings (P/E)
- -2.5
- Beta (1Y)
- 2.19
- Revenue Growth
- 90.73%
- EPS Growth
- 12.93%
- Country
- Hong Kong
- Employees
- 63
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Based in the People's Republic of China, Shanghai Bio-heart Biological Technology Co., Ltd. is a medical technology firm specializing in interventional cardiovascular devices. Its core business revolves around delivering bioresorbable scaffolds (BRS)...
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Financial Statement Overview
Summary
Financials remain weak overall: despite a 2025 revenue rebound, profitability is deeply negative (loss-making with negative gross profit and large operating losses) and cash flow is persistently negative with ongoing free-cash-flow burn. The main support is a low-debt balance sheet, but continued losses are eroding equity over time.
Income Statement
12Very NegativeBalance Sheet
68PositiveCash Flow
17Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 37.85M | 43.77M | 0 | 0 | 0 | 0 |
| Gross Profit | -868.26K | -157.81K | 0 | -23.60M | -24.25M | -13.27M |
| EBITDA | -66.12M | -52.13M | -52.87M | -143.27M | -229.43M | -396.42M |
| Net Income | -74.33M | -68.24M | -87.94M | -175.89M | -204.24M | -361.45M |
Balance Sheet | ||||||
| Total Assets | 790.68M | 832.83M | 733.78M | 817.90M | 981.52M | 1.11B |
| Cash, Cash Equivalents and Short-Term Investments | 237.83M | 248.63M | 202.39M | 369.44M | 451.32M | 708.53M |
| Total Debt | 180.43M | 12.73M | 8.28M | 1.76M | 18.11M | 22.45M |
| Total Liabilities | 211.92M | 220.47M | 53.24M | 44.04M | 66.47M | 80.04M |
| Stockholders Equity | 402.08M | 435.00M | 660.47M | 748.41M | 883.21M | 995.69M |
Cash Flow | ||||||
| Free Cash Flow | -78.90M | -72.91M | -166.69M | -66.74M | -170.65M | -147.28M |
| Operating Cash Flow | -69.25M | -65.48M | -119.55M | -49.03M | -140.62M | -105.45M |
| Investing Cash Flow | -24.53M | -39.78M | -46.03M | -28.86M | -100.69M | -33.73M |
| Financing Cash Flow | 224.31K | -1.74M | -2.44M | -5.82M | -35.18M | 383.68M |
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2185, the sentiment is Negative. The current price of 0.98 is below the 20-day moving average (MA) of 1.19, below the 50-day MA of 1.52, and below the 200-day MA of 3.33, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 17.37 is Positive, neither overbought nor oversold. The STOCH value of 4.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2185.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Peers Comparison
Overall Rating
HK:231569Neutral
HK:218157Neutral
HK:217145Neutral
HK:249643Neutral
HK:289842Neutral- HK:218542Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2315 | 69Neutral | HKD 17.02B | 38.16 | 15.94% | ― | 48.04% | 166.72% |
| HK:2181 | 57Neutral | HKD 1.79B | 17.76 | 48.25% | ― | 88.38% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2171 | 45Neutral | HKD 6.32B | -56.08 | -9.45% | ― | 68.12% | 81.84% |
| HK:2496 | 43Neutral | HKD 1.05B | -13.84 | 85.52% | ― | -55.22% | 57.76% |
| HK:2898 | 42Neutral | HKD 970.43M | -8.74 | -39.21% | ― | ― | ― |
| HK:2185 | 42Neutral | HKD 226.38M | -2.54 | -17.76% | ― | 90.73% | 12.93% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2185 | Shanghai Bio-Heart Biological Technology Co., Ltd. Class H | 0.93 | -7.77 | -89.31% | |
| HK:2171 | CARsgen Therapeutics Holdings Ltd. | 10.63 | -6.92 | -39.43% | |
| HK:2181 | Mabpharm Limited | 0.43 | -0.09 | -16.35% | |
| HK:2315 | Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H | 38.30 | 9.06 | 30.98% | |
| HK:2496 | Wuhan YZY Biopharma Co., Ltd. Class H | 4.00 | -3.01 | -42.94% | |
| HK:2898 | Sunho Biologics,Inc. | 6.39 | -1.61 | -20.13% |
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Corporate Events
Shanghai Bio-heart Switches to CASBE and Proposes New Auditor
Shanghai Bio-heart Biological Technology’s board has approved the adoption of China Accounting Standards for Business Enterprises (CASBE) as the sole basis for preparing its financial reports, eliminating the parallel use of International Finan...
Shanghai Bio-heart Shareholders Back New Independent Director in 2026 EGM
Shanghai Bio-heart Biological Technology Co., Ltd., a Hong Kong-listed PRC biotechnology company, focuses on cardiovascular-related medical technology and operates from Shanghai’s Zhangjiang Hi-Tech Park. Its capital structure features H shares...
Shanghai Bio-Heart Sets Board and Committee Structure to Strengthen Governance
Shanghai Bio-Heart Biological Technology Co., Ltd., a Hong Kong-listed biotech company, has outlined the composition of its board of directors, comprising three executive directors and three independent non-executive directors. The board includes Phi...
Shanghai Bio-Heart Calls 2026 EGM to Appoint New Independent Director
Shanghai Bio-Heart Biological Technology Co., Ltd. has called its first extraordinary general meeting of 2026 for October 9 in Shanghai to seek shareholder approval for appointing Ms. Qianwen Fei as an independent non-executive director, with her ter...
Shanghai Bio-heart Says Director’s Regulatory Warning Won’t Hit Operations
Shanghai Bio-heart Biological Technology Co., Ltd. has disclosed that independent non-executive director Mr. Chen Yiqing received a formal warning letter from the Tianjin Securities Regulatory Bureau related to his former role at Zhongyuan Concord Ce...
Shanghai Bio-heart Strikes Strategic Pact to Commercialise Bioabsorbable Coronary Stent
Shanghai Bio-heart Biological Technology Co., Ltd. has signed a strategic cooperation agreement with Shanghai Shenqi Medical Technology Co., Ltd. to jointly advance the commercialisation and clinical application of its BioHeart bioabsorbable rapamyci...
AngioCare hires renal denervation veteran to drive global Iberis therapy push
Shanghai Bio-heart’s subsidiary AngioCare has appointed veteran cardiovascular and metabolic disease specialist Giorgio Gobbi as Vice President, Global Therapy Development, to lead global therapy development for the Iberis Renal Denervation Sys...
Shanghai Bio-Heart Sets October EGM to Strengthen Board Independence
Shanghai Bio-Heart Biological Technology Co., Ltd., a Hong Kong-listed PRC biotech firm focused on medical technology, operates through a Class H share structure and is governed by a board led by chairman and executive director Philip Li Wang. Its bl...
Shanghai Bio-Heart Narrows Market Path With New Stent Approval Amid Wider Interim Loss
Shanghai Bio-Heart Biological Technology Co., Ltd., a Chinese cardiovascular device maker, develops and commercializes interventional products such as bioabsorbable drug-eluting stents and the Iberis system for ischemic heart disease. The company has...
Shanghai Bio-Heart reshapes board as independent director exits
Shanghai Bio-Heart Biological Technology has announced the resignation of independent non-executive director Yiqing Chen, who is stepping down to focus on other business commitments but will remain in post until shareholders approve a successor. Chen...
Shanghai Bio-heart Sets Board Meeting to Review Interim Results and Possible Dividend
Shanghai Bio-heart Biological Technology Co., Ltd., a Hong Kong-listed Chinese biotech firm under stock code 2185, operates in the biological and medical technology industry with a focus on innovative healthcare products and services in China and bey...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026